These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 37184411)
1. Chen J; Liu Y; Jia W; Xu X; Sun G; Wang T; Li J; Zhang G; Jing R; Sun H; Xu Y; Liu Y Microbiol Spectr; 2023 Jun; 11(3):e0487322. PubMed ID: 37184411 [TBL] [Abstract][Full Text] [Related]
2. In-vitro activities of essential antimicrobial agents including aztreonam/avibactam, eravacycline, colistin and other comparators against carbapenem-resistant bacteria with different carbapenemase genes: A multi-centre study in China, 2021. Wu Y; Chen J; Zhang G; Li J; Wang T; Kang W; Zhang J; Sun H; Liu Y; Xu Y Int J Antimicrob Agents; 2024 Nov; 64(5):107341. PubMed ID: 39304121 [TBL] [Abstract][Full Text] [Related]
3. Comparative Activities of Novel Therapeutic Agents against Molecularly Characterized Clinical Carbapenem-Resistant Teo JQ; Chang HY; Tan SH; Tang CY; Ong RT; Ko KKK; Chung SJ; Tan TT; Kwa AL Microbiol Spectr; 2023 Jun; 11(3):e0100223. PubMed ID: 37184408 [TBL] [Abstract][Full Text] [Related]
4. Guo Y; Han R; Jiang B; Ding L; Yang F; Zheng B; Yang Y; Wu S; Yin D; Zhu D; Hu F; Microbiol Spectr; 2022 Aug; 10(4):e0185422. PubMed ID: 35862963 [TBL] [Abstract][Full Text] [Related]
5. In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019-2021. Wise MG; Karlowsky JA; Mohamed N; Kamat S; Sahm DF Eur J Clin Microbiol Infect Dis; 2023 Sep; 42(9):1135-1143. PubMed ID: 37526796 [TBL] [Abstract][Full Text] [Related]
6. In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula. Sonnevend Á; Ghazawi A; Darwish D; Barathan G; Hashmey R; Ashraf T; Rizvi TA; Pál T Int J Infect Dis; 2020 Oct; 99():253-259. PubMed ID: 32738488 [TBL] [Abstract][Full Text] [Related]
7. Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies. Xu C; Wei X; Jin Y; Bai F; Cheng Z; Chen S; Pan X; Wu W Microbiol Spectr; 2022 Oct; 10(5):e0139022. PubMed ID: 35972286 [TBL] [Abstract][Full Text] [Related]
8. Antimicrobial activities of aztreonam-avibactam and comparator agents tested against Enterobacterales from European hospitals analysed by geographic region and infection type (2019-2020). Sader HS; Mendes RE; Arends SJR; Carvalhaes CG; Castanheira M Eur J Clin Microbiol Infect Dis; 2022 Mar; 41(3):477-487. PubMed ID: 35041100 [TBL] [Abstract][Full Text] [Related]
9. Yang Y; Guo Y; Yin D; Zheng Y; Wu S; Zhu D; Hu F Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33139291 [TBL] [Abstract][Full Text] [Related]
10. In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Malaysia: Results from the ATLAS Programme, 2013 to 2019. Tuan Soh TS; Salvinder S; Chen VSY Med J Malaysia; 2022 Mar; 77(2):174-184. PubMed ID: 35338624 [TBL] [Abstract][Full Text] [Related]
11. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018). Piérard D; Stone GG BMC Infect Dis; 2021 Jun; 21(1):600. PubMed ID: 34162341 [TBL] [Abstract][Full Text] [Related]
12. In vitro activity of ceftazidime/avibactam against Gram-negative strains in Colombia 2014-2018. Lemos-Luengas EV; Rentería-Valoyes S; Cárdenas-Isaza P; Ramos-Castaneda JA J Glob Antimicrob Resist; 2022 Jun; 29():141-146. PubMed ID: 35257971 [TBL] [Abstract][Full Text] [Related]
13. Rapid characterization of carbapenem-resistant Enterobacterales by multiplex lateral flow assay and detection of ceftazidime-avibactam-aztreonam synergy. Kalaivani R; Kali A; Surendran R; Sujaritha T; Ganesh Babu CP Indian J Med Microbiol; 2024; 47():100530. PubMed ID: 38246242 [TBL] [Abstract][Full Text] [Related]
14. Ceftazidime-Avibactam plus aztreonam synergistic combination tested against carbapenem-resistant Enterobacterales characterized phenotypically and genotypically: a glimmer of hope. Taha R; Kader O; Shawky S; Rezk S Ann Clin Microbiol Antimicrob; 2023 Mar; 22(1):21. PubMed ID: 36945002 [TBL] [Abstract][Full Text] [Related]
15. In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017). Ko WC; Stone GG Ann Clin Microbiol Antimicrob; 2020 Apr; 19(1):14. PubMed ID: 32238155 [TBL] [Abstract][Full Text] [Related]
17. Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. Sader HS; Carvalhaes CG; Arends SJR; Castanheira M; Mendes RE J Antimicrob Chemother; 2021 Feb; 76(3):659-666. PubMed ID: 33276387 [TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755 [TBL] [Abstract][Full Text] [Related]
19. Activity of aztreonam/avibactam and ceftazidime/avibactam against Enterobacterales with carbapenemase-independent carbapenem resistance. Mushtaq S; Vickers A; Woodford N; Livermore DM Int J Antimicrob Agents; 2024 Mar; 63(3):107081. PubMed ID: 38176458 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of Dilution Susceptibility Testing Methods for Aztreonam in Combination with Avibactam against Enterobacterales. Kelley CJ; Kennedy-Mendez A; Walser ON; Thwaites MT; Arhin FF; Pillar CM; Hufnagel DA Microbiol Spectr; 2022 Dec; 10(6):e0360122. PubMed ID: 36342288 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]